{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:14:44Z","timestamp":1794374084646,"version":"4.9.0"},"reference-count":116,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"unspecified","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2026,2,28]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Chimeric antigen receptor (CAR)-T cell therapies have transformed the management of relapsed or refractory haematological malignancies and are now being adapted for severe B-cell mediated autoimmune disease, including neuroimmunological disorders. Their appeal lies in deep and durable B-cell depletion within lymphoid tissues and target organs, with the potential to induce long-lasting, treatment-free remission. At the same time, broader application is constrained by serious toxicities, in particular, neurological complications such as immune effector cell-associated neurotoxicity syndrome (ICANS) and more recently recognised movement, cerebellar, cranial nerve and peripheral nerve syndromes. In this review, we outline the biological principles of CAR-T cell therapy and summarise the emerging experience in neuroimmunology. We draw on data from both oncology and early autoimmune trials to describe the clinical spectrum, timing and proposed mechanisms of CAR-T cell-related neurotoxicity and to distinguish ICANS from later and more focal toxicities. As CAR-T cell therapies move from cancer centres into the care of patients with refractory neuroimmunological disease, neurologists will need a detailed understanding of both their therapeutic promise and their neurological risks, and close collaboration within multidisciplinary teams will be essential to deliver these treatments safely.<\/jats:p>","DOI":"10.1136\/bmjno-2025-001491","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:30:19Z","timestamp":1773934219000},"page":"e001491","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Neurological implications of chimeric antigen receptor-T cell therapy"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct04146051","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04146051","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06799247","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06193889","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05349006","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06588491","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06550141","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2976-2845","authenticated-orcid":false,"given":"Daniel G","family":"Raffoul","sequence":"first","affiliation":[{"name":"Department of Neurology, Austin Health, Heidelberg, Victoria, Australia"},{"name":"Neuroimmunology Centre, Department of Neurology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0371-3666","authenticated-orcid":false,"given":"Izanne","family":"Roos","sequence":"additional","affiliation":[{"name":"Neuroimmunology Centre, Department of Neurology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia"},{"name":"CORe, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Mulazzani","sequence":"additional","affiliation":[{"name":"Neuroimmunology Centre, Department of Neurology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia"},{"name":"Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6404-9768","authenticated-orcid":false,"given":"Mastura","family":"Monif","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of MS and Neuroimmunology, Alfred Health, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Garber","sequence":"additional","affiliation":[{"name":"Department of Neurology, Westmead Hospital, Sydney, New South Wales, Australia"},{"name":"Westmead Clinical School, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4278-7003","authenticated-orcid":false,"given":"Anneke","family":"van der Walt","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3238-4630","authenticated-orcid":false,"given":"Jennifer","family":"Massey","sequence":"additional","affiliation":[{"name":"Department of Neurology, St Vincent\u2019s Hospital Sydney, Sydney, New South Wales, Australia"},{"name":"School of Clinical Medicine, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeriya","family":"Kuznetsova","sequence":"additional","affiliation":[{"name":"Neuroimmunology Centre, Department of Neurology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia"},{"name":"CORe, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassie","family":"Nesbitt","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of MS and Neuroimmunology, Alfred Health, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, University Hospital, Geelong, Geelong, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Dowling","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Ruderman","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia"},{"name":"Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arian","family":"Lasocki","sequence":"additional","affiliation":[{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"Department of Radiology, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine S","family":"Tam","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Alfred Health, Melbourne, Victoria, Australia"},{"name":"Central Clinical School, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J","family":"Harrison","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3778-1376","authenticated-orcid":false,"given":"Tomas","family":"Kalincik","sequence":"additional","affiliation":[{"name":"Neuroimmunology Centre, Department of Neurology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia"},{"name":"CORe, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"2026051208152895000_8.1.e001491.1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.46989\/001c.115919","article-title":"Outcomes of Autologous stem cell transplantation in patients with primary refractory Diffuse Large B-cell lymphoma who demonstrate chemosensitivity to salvage chemotherapy","volume":"6","author":"Rauf","year":"2024","journal-title":"Clinical Hematology International"},{"key":"2026051208152895000_8.1.e001491.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"2026051208152895000_8.1.e001491.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-00323-z"},{"key":"2026051208152895000_8.1.e001491.4","doi-asserted-by":"crossref","first-page":"1613878","DOI":"10.3389\/fimmu.2025.1613878","article-title":"CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon","volume":"16","author":"Wu","year":"2025","journal-title":"Front Immunol"},{"key":"2026051208152895000_8.1.e001491.5","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32866-0","article-title":"Potential solutions for manufacture of CAR T cells in cancer immunotherapy","volume":"13","author":"Blache","year":"2022","journal-title":"Nat Commun"},{"key":"2026051208152895000_8.1.e001491.6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756"},{"key":"2026051208152895000_8.1.e001491.7","doi-asserted-by":"crossref","first-page":"1562662","DOI":"10.3389\/fimmu.2025.1562662","article-title":"Chimeric autoantibody receptor T cells specifically eliminate Graves\u2019 Disease autoreactive B cells","volume":"16","author":"Cheever","year":"2025","journal-title":"Front Immunol"},{"key":"2026051208152895000_8.1.e001491.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01637-z"},{"key":"2026051208152895000_8.1.e001491.9","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature New Biol"},{"key":"2026051208152895000_8.1.e001491.10","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14076"},{"key":"2026051208152895000_8.1.e001491.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308917"},{"key":"2026051208152895000_8.1.e001491.12","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226142"},{"key":"2026051208152895000_8.1.e001491.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725"},{"key":"2026051208152895000_8.1.e001491.14","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"key":"2026051208152895000_8.1.e001491.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3"},{"key":"2026051208152895000_8.1.e001491.16","first-page":"e1426","article-title":"Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis","volume":"95","author":"Tomschik","year":"2020","journal-title":"Neurology (ECronicon)"},{"key":"2026051208152895000_8.1.e001491.17","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-024-00701-1"},{"key":"2026051208152895000_8.1.e001491.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00194-1"},{"key":"2026051208152895000_8.1.e001491.19","doi-asserted-by":"crossref","unstructured":"Vu T , Tekce HD , Rivner M , et al . Efficacy and Safety of Autologous BCMA-directed mRNA CAR T-Cell Therapy in Generalized Myasthenia Gravis: Results from a Phase 2b Randomized Placebo-controlled Trial (S34.002). Neurology (ECronicon) 2025;104. doi:10.1212\/WNL.0000000000212220","DOI":"10.1212\/WNL.0000000000212220"},{"key":"2026051208152895000_8.1.e001491.20","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(23)00375-7"},{"key":"2026051208152895000_8.1.e001491.21","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","article-title":"Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells","volume":"112","author":"Motte","year":"2024","journal-title":"Neuron"},{"key":"2026051208152895000_8.1.e001491.22","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1007\/s00415-024-12367-4","article-title":"Bispecific BCMA\/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report","volume":"271","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"key":"2026051208152895000_8.1.e001491.23","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/acn3.70167","article-title":"Durability of Response to B-Cell Maturation Antigen-Directed mRNA Cell Therapy in Myasthenia Gravis","volume":"12","author":"Chahin","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"2026051208152895000_8.1.e001491.24","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101794","article-title":"Anti-CD19 CAR-T cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome","volume":"5","author":"Wickel","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026051208152895000_8.1.e001491.25","doi-asserted-by":"crossref","unstructured":"Haghikia A , Borie D , Chung J , et al . Design of KYSA-6, a Phase 2, Open-label, Multicenter Study of KYV-101, a Novel Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory Generalized Myasthenia Gravis (P7-11.034). Neurology (ECronicon) 2025;104. doi:10.1212\/WNL.0000000000210631","DOI":"10.1212\/WNL.0000000000210631"},{"key":"2026051208152895000_8.1.e001491.26","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1001\/jamaneurol.2023.1184","article-title":"Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis","volume":"80","author":"Kalincik","year":"2023","journal-title":"JAMA Neurol"},{"key":"2026051208152895000_8.1.e001491.27","doi-asserted-by":"crossref","unstructured":"Kalincik T , Sharmin S , Roos I , et al . Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis. Brain (Bacau) 2025.:awaf286. doi:10.1093\/brain\/awaf286","DOI":"10.1093\/brain\/awaf286"},{"key":"2026051208152895000_8.1.e001491.28","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-332790"},{"key":"2026051208152895000_8.1.e001491.29","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-331748"},{"key":"2026051208152895000_8.1.e001491.30","doi-asserted-by":"publisher","DOI":"10.1038\/nri3871"},{"key":"2026051208152895000_8.1.e001491.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"2026051208152895000_8.1.e001491.32","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"2026051208152895000_8.1.e001491.33","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1016\/j.cell.2025.09.020","article-title":"Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis","volume":"188","author":"Qin","year":"2025","journal-title":"Cell"},{"key":"2026051208152895000_8.1.e001491.34","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12084"},{"key":"2026051208152895000_8.1.e001491.35","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol"},{"key":"2026051208152895000_8.1.e001491.36","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26626"},{"key":"2026051208152895000_8.1.e001491.37","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26049"},{"key":"2026051208152895000_8.1.e001491.38","unstructured":"Sharmin S , Roos I , Siriratnam P , et al . How patients with neuromyelitis optica spectrum disorder accumulate disability. ECTRIMS; 2024."},{"key":"2026051208152895000_8.1.e001491.39","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"2026051208152895000_8.1.e001491.40","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-332851"},{"key":"2026051208152895000_8.1.e001491.41","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2025-337039"},{"key":"2026051208152895000_8.1.e001491.42","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25648"},{"key":"2026051208152895000_8.1.e001491.43","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200292","article-title":"CD19-Directed CAR T-Cells in a Patient With Refractory MOGAD: Clinical and Immunologic Follow-Up for 1 Year","volume":"11","author":"Cabrera-Maqueda","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026051208152895000_8.1.e001491.44","doi-asserted-by":"publisher","DOI":"10.1177\/1756285611405564"},{"key":"2026051208152895000_8.1.e001491.45","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2025-001318","article-title":"Evaluation and treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy","volume":"7","author":"Kiers","year":"2025","journal-title":"BMJ Neurol Open"},{"key":"2026051208152895000_8.1.e001491.46","doi-asserted-by":"crossref","first-page":"100704","DOI":"10.1016\/j.medj.2025.100704","article-title":"Anti-BCMA CAR-T cell therapy in relapsed\/refractory chronic inflammatory demyelinating polyneuropathy","volume":"6","author":"Dong","year":"2025","journal-title":"Med"},{"key":"2026051208152895000_8.1.e001491.47","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S1474-4422(25)00199-1","article-title":"CD19-targeted CAR T-cell therapy for treatment-refractory autoimmune neuropathies","volume":"24","author":"Motte","year":"2025","journal-title":"Lancet Neurol"},{"key":"2026051208152895000_8.1.e001491.48","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-024-01012-3"},{"key":"2026051208152895000_8.1.e001491.49","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2403227121","article-title":"Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome","volume":"121","author":"Faissner","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026051208152895000_8.1.e001491.50","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210669","article-title":"Design of KYSA-8, A Phase 2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Treatment-Refractory Stiff-Person Syndrome (P2-8.018)","volume":"104","author":"Piquet","year":"2025","journal-title":"Neurology (ECronicon)"},{"key":"2026051208152895000_8.1.e001491.51","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-025-01112-8"},{"key":"2026051208152895000_8.1.e001491.52","doi-asserted-by":"crossref","DOI":"10.1007\/s00296-024-05772-5","article-title":"Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review","volume":"45","author":"Kattamuri","year":"2025","journal-title":"Rheumatol Int"},{"key":"2026051208152895000_8.1.e001491.53","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00903-0"},{"key":"2026051208152895000_8.1.e001491.54","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1392831","article-title":"Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: systematic review and meta-analysis","volume":"15","author":"Han","year":"2024","journal-title":"Front Neurol"},{"key":"2026051208152895000_8.1.e001491.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"2026051208152895000_8.1.e001491.56","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"The Lancet"},{"key":"2026051208152895000_8.1.e001491.57","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00591-X"},{"key":"2026051208152895000_8.1.e001491.58","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1093\/neuonc\/noad118","article-title":"Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells","volume":"25","author":"Karschnia","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026051208152895000_8.1.e001491.59","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01969-y"},{"key":"2026051208152895000_8.1.e001491.60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T Cell-Associated Neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front Immunol"},{"key":"2026051208152895000_8.1.e001491.61","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173096","article-title":"CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells","volume":"134","author":"Storci","year":"2024","journal-title":"J Clin Invest"},{"key":"2026051208152895000_8.1.e001491.62","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4"},{"key":"2026051208152895000_8.1.e001491.63","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/acn3.51348","article-title":"Brain dysfunction in COVID-19 and CAR-T therapy: cytokine storm-associated encephalopathy","volume":"8","author":"Pensato","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"2026051208152895000_8.1.e001491.64","doi-asserted-by":"crossref","DOI":"10.1093\/noajnl\/vdad135","article-title":"Functional connectivity MRI provides an imaging correlate for chimeric antigen receptor T-cell-associated neurotoxicity","volume":"5","author":"Stoecklein","year":"2023","journal-title":"Neuro-Oncology Advances"},{"key":"2026051208152895000_8.1.e001491.65","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319"},{"key":"2026051208152895000_8.1.e001491.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.03.006"},{"key":"2026051208152895000_8.1.e001491.67","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.autrev.2015.06.002","article-title":"A spectrum of inflammation and demyelination in acute disseminated encephalomyelitis (ADEM) of children","volume":"14","author":"Esposito","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2026051208152895000_8.1.e001491.68","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jtct.2022.03.023","article-title":"Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy","volume":"28","author":"Hoogland","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2026051208152895000_8.1.e001491.69","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-202851","article-title":"Cognitive and Psychological Recovery from the Immune Effector Cell Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell (CAR-T) Therapy","volume":"144","author":"Kuznetsova","year":"2024","journal-title":"Blood"},{"key":"2026051208152895000_8.1.e001491.70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"2026051208152895000_8.1.e001491.71","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1080\/10428194.2022.2074990","article-title":"Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy","volume":"63","author":"Lapidus","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"2026051208152895000_8.1.e001491.72","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011669"},{"key":"2026051208152895000_8.1.e001491.73","doi-asserted-by":"crossref","DOI":"10.1148\/rg.230069","article-title":"Neuroimaging Features of Cytokine-related Diseases","volume":"44","author":"Kurokawa","year":"2024","journal-title":"Radiographics"},{"key":"2026051208152895000_8.1.e001491.74","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S1470-2045(24)00715-0","article-title":"Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee","volume":"26","author":"Graham","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026051208152895000_8.1.e001491.75","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/bloodadvances.2025017378","article-title":"Routine prophylaxis with levetiracetam offers no benefit in CD19 CAR-T for LBCL: a multicenter propensity-matched study","volume":"9","author":"Galli","year":"2025","journal-title":"Blood Adv"},{"key":"2026051208152895000_8.1.e001491.76","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"2026051208152895000_8.1.e001491.77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.04.001"},{"key":"2026051208152895000_8.1.e001491.78","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-201274","article-title":"Retrospective Comparison of the Roles of Tocilizumab and Siltuximab in the Management of Toxicity in CAR-T Cell Therapy for Relapsed\/Refractory B-NHL","volume":"144","author":"Liu","year":"2024","journal-title":"Blood"},{"key":"2026051208152895000_8.1.e001491.79","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1002\/cncr.35316","article-title":"Impact of tocilizumab on anti\u2010CD19 chimeric antigen receptor T\u2010cell therapy in B\u2010cell acute lymphoblastic leukemia","volume":"130","author":"Wang","year":"2024","journal-title":"Cancer"},{"key":"2026051208152895000_8.1.e001491.80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-155846"},{"key":"2026051208152895000_8.1.e001491.81","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011027"},{"key":"2026051208152895000_8.1.e001491.82","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02404-6"},{"key":"2026051208152895000_8.1.e001491.83","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010653"},{"key":"2026051208152895000_8.1.e001491.84","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/blood.2024026586","article-title":"Itacitinib for the prevention of IEC therapy\u2013associated CRS: results from the 2-part phase 2 INCB 39110-211 study","volume":"146","author":"Frigault","year":"2025","journal-title":"Blood"},{"key":"2026051208152895000_8.1.e001491.85","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009961"},{"key":"2026051208152895000_8.1.e001491.86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2026051208152895000_8.1.e001491.87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2026051208152895000_8.1.e001491.88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"2026051208152895000_8.1.e001491.89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42466-021-00166-5","article-title":"Neurological management and work-up of neurotoxicity associated with CAR T cell therapy","volume":"4","author":"M\u00f6hn","year":"2022","journal-title":"Neurol Res Pract"},{"key":"2026051208152895000_8.1.e001491.90","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16174","article-title":"Patterns of neurotoxicity among patients receiving chimeric antigen receptor T-cell therapy: A single-centre cohort study","volume":"31","author":"Sales","year":"2024","journal-title":"Eur J Neurol"},{"key":"2026051208152895000_8.1.e001491.91","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab077"},{"key":"2026051208152895000_8.1.e001491.92","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz410"},{"key":"2026051208152895000_8.1.e001491.93","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2020.1805239"},{"key":"2026051208152895000_8.1.e001491.94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2019.11.007"},{"key":"2026051208152895000_8.1.e001491.95","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/17474086.2025.2542867","article-title":"Cognitive impairment in hematology patients planned for chimeric antigen receptor T-cell therapy","volume":"18","author":"Kuznetsova","year":"2025","journal-title":"Expert Rev Hematol"},{"key":"2026051208152895000_8.1.e001491.96","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02276-w"},{"key":"2026051208152895000_8.1.e001491.97","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas","volume":"637","author":"Monje","year":"2025","journal-title":"Nature New Biol"},{"key":"2026051208152895000_8.1.e001491.98","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"2026051208152895000_8.1.e001491.99","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.2023020571","article-title":"Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells","volume":"142","author":"Karschnia","year":"2023","journal-title":"Blood"},{"key":"2026051208152895000_8.1.e001491.100","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.131","article-title":"Parkinson-like neurotoxicity in female patients treated with idecabtagene-vicleucel","volume":"8","author":"Couturier","year":"2024","journal-title":"Hemasphere"},{"key":"2026051208152895000_8.1.e001491.101","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01564-7"},{"key":"2026051208152895000_8.1.e001491.102","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jamaneurol.2024.2506","article-title":"Parkinsonism Following Chimeric Antigen Receptor T Cell Therapy","volume":"81","author":"Gudera","year":"2024","journal-title":"JAMA Neurol"},{"key":"2026051208152895000_8.1.e001491.103","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1016\/j.jtct.2023.12.532","article-title":"Clinical Experience with Cranial Nerve Impairment in the Cartitude-1, Cartitude-2 Cohorts a, B and C, and Cartitude-4 Studies of Ciltacabtagene Autoleucel (Cilta-cel)","volume":"30","author":"van de Donk","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2026051208152895000_8.1.e001491.104","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jtct.2024.12.002","article-title":"Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS Data","volume":"31","author":"Ellithi","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"2026051208152895000_8.1.e001491.105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006059","article-title":"Diabetes insipidus and Guillain-Barr\u00e9-like syndrome following CAR-T cell therapy: a case report","volume":"11","author":"Koch","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026051208152895000_8.1.e001491.106","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900"},{"key":"2026051208152895000_8.1.e001491.107","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1182\/blood.2024025679","article-title":"Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy","volume":"144","author":"Desch\u00eanes-Simard","year":"2024","journal-title":"Blood"},{"key":"2026051208152895000_8.1.e001491.108","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-24-0378","article-title":"FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma","volume":"30","author":"Natrajan","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026051208152895000_8.1.e001491.109","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(25)00091-8"},{"key":"2026051208152895000_8.1.e001491.110","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-205103","article-title":"CD19-Directed CAR T Cell Therapy in 4 Patients with Refractory Multiple Sclerosis","volume":"144","author":"Richter","year":"2024","journal-title":"Blood"},{"key":"2026051208152895000_8.1.e001491.111","doi-asserted-by":"crossref","first-page":"S1056","DOI":"10.1016\/S2152-2650(25)02858-7","article-title":"CT-1326: HHV-6 Reactivation in the Era of CAR T-Cell Therapy: A Systematic Review of Emerging Challenges","volume":"25","author":"Khan","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026051208152895000_8.1.e001491.112","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood.2024024145","article-title":"Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients","volume":"144","author":"Kampouri","year":"2024","journal-title":"Blood"},{"key":"2026051208152895000_8.1.e001491.113","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41586-023-06704-2","article-title":"Latent human herpesvirus 6 is reactivated in CAR T cells","volume":"623","author":"Lareau","year":"2023","journal-title":"Nature New Biol"},{"key":"2026051208152895000_8.1.e001491.114","doi-asserted-by":"crossref","first-page":"e870","DOI":"10.1016\/S2352-3026(21)00316-1","article-title":"Progressive multifocal leukoencephalopathy in the era of chimeric antigen receptor T-cell therapy","volume":"8","author":"Mackenzie","year":"2021","journal-title":"Lancet Haematol"},{"key":"2026051208152895000_8.1.e001491.115","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.11.021"},{"key":"2026051208152895000_8.1.e001491.116","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N Engl J Med"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2025-001491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:16:27Z","timestamp":1778598987000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2025-001491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":116,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,19]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjno-2025-001491"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2025-001491","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}